MaxCyte Quarterly Cash Flow Statement
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MaxCyte free cash flow
In the quarter ended Sep 30, 2026, MaxCyte generated -$5.5 million of operating cash flow and spent $59,000 on capital expenditures. That left free cash flow of -$5.6 million, a free-cash-flow margin of -54.8% of revenue. MaxCyte returned $4.0 million to shareholders through share repurchases.
Summary generated from market data by MetaCap's automated system. Methodology
MaxCyte cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -4.76M | -8.87M | -4.75M | -9.60M | -12.42M | -12.36M | -10.26M | -10.60M | -11.56M | -9.38M | -9.53M | -5.28M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 900.00K | 978.00K | 1.05M | 1.07M | 1.07M | 1.10M | 1.10M | 1.06M | 1.07M | 1.08M | 1.11M | 1.10M |
| Stock-Based Compensation | 963.00K | 1.16M | 1.14M | 706.00K | 1.95M | 3.51M | 3.04M | 3.13M | 3.37M | 3.56M | 3.02M | 3.57M |
| Change in Working Capital | -2.11M | -13.00K | -5.02M | 1.48M | 2.02M | -585.00K | -7.16M | -945.00K | 3.81M | 1.68M | -3.37M | 2.67M |
| Operating Cash Flow | -5.51M | -4.66M | -8.17M | -2.69M | -7.46M | -9.85M | -14.41M | -7.82M | -4.39M | -4.83M | -10.56M | 981.00K |
| Capital Expenditures | -59.00K | -62.00K | -72.00K | -231.00K | -300.00K | -584.00K | -653.00K | -147.00K | -406.00K | -294.00K | -804.00K | -915.00K |
| Investing Cash Flow | 7.86M | 6.57M | 2.66M | 9.68M | 5.19M | 1.54M | 9.53M | -1.67M | 3.61M | 19.39M | -14.40M | -4.14M |
| Share Repurchases | -4.02M | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | -4.02M | -1.42M | 5.00K | 105.00K | 14.00K | 154.00K | 383.00K | 412.00K | 228.00K | 713.00K | 703.00K | 493.00K |
| Net Change in Cash | -1.67M | 485.00K | -5.51M | 7.09M | -2.25M | -8.16M | -4.50M | -9.07M | -555.00K | 15.26M | -24.26M | -2.67M |
| Free Cash Flow | -5.57M | -4.72M | -8.24M | -2.92M | -7.76M | -10.44M | -15.06M | -7.97M | -4.80M | -5.13M | -11.37M | 66.00K |
This table shows 12 quarterly periods of MaxCyte's cash flow statement, from Q3 2026 back to Q4 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a cash flow statement?